1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US CAR T-cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US CAR T-cell Therapy Market, by Product
8.1.1 Abecma (idecabtagene vicleucel)
8.1.1.1. Market Revenue and Forecast
8.1.2. Breyanzi (lisocabtagene maraleucel)
8.1.2.1. Market Revenue and Forecast
8.1.3. Carvykti (ciltacabtagene autoleucel)
8.1.3.1. Market Revenue and Forecast
8.1.4. Kymriah (tisagenlecleucel)
8.1.4.1. Market Revenue and Forecast
8.1.5. Tecartus (brexucabtagene autoleucel)
8.1.5.1. Market Revenue and Forecast
8.1.6. Yescarta (axicabtagene ciloleucel)
8.1.6.1. Market Revenue and Forecast
9.1. US CAR T-cell Therapy Market, by Disease Indication
9.1.1. Leukemia
9.1.1.1. Market Revenue and Forecast
9.1.2. Lymphoma
9.1.2.1. Market Revenue and Forecast
9.1.3. Multiple Myeloma
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. US CAR T-cell Therapy Market, by End-Use
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Disease Indication
11.1.4.3. Market Revenue and Forecast, by End-Use
12.1. Bristol-Myers Squibb Company
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Gilead Sciences, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson Services, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. JW Therapeutics (Shanghai) Co., Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. bluebird bio, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sangamo Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sorrento Therapeutics, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GSK plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
